FDG PET For Myocardial Viability Gains Positive Coverage Decision From CMS
This article was originally published in The Gray Sheet
Executive Summary
FDG positron emission tomography's high specificity in determining myocardial viability following revascularization establishes the technology's value as a stand-alone diagnostic, according to a Feb. 20 1national coverage decision issued by CMS
You may also be interested in...
PET Cancer Coverage Decision Saves Dense-Breast Indication For Another Day
The Centers for Medicare & Medicaid Services is inviting interested parties to submit a separate coverage request for FDG-PET in women who have dense breast tissue
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.